First-line analysis of urothelial carcinoma offers new insights into treatment choice and outcomes
A real-world evaluation of treatment regimens and clinical outcomes in patients with metastatic urothelial carcinoma revealed that more than 50% of patients had not received first-line systemic therapy. Of those who did, unadjusted real-world overall survival (OS) was longer in patients receiving first-line cisplatin compared to other initial options.1 “Real-world data related to treatment...
Read More